Article2025
Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis
María-Victoria Mateos, Vânia Hungria, Meral Beksaç, Paweł Robak, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Gracia Martínez, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, Phoebe Joy Ho, Roman Hájek, Sebastian Grosicki, S. Yousuf Zafar, Al-Ola Abdallah, Jorge Mouro, Zeyad Khalaf, Hena Baig, Ainslee Moore, Chee Paul Lin, Maureen Nichols, Ianire Garrobo-Calleja, Sybil Varghese, Nick Pirooz, Shing Yip Lee, Lydia Eccersley, Elisabet E. Manasanch,
Article2025
Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf)–Based Regimens From the DREAMM-7 and DREAMM-8 Trials
Paweł Robak, Vânia Hungria, Luděk Pour, Kihyun Kım, Sergey Voloshin, Hanlon Sia, Esther González García, Chang‐Ki Min, Marcelo Pitombeira de Lacerda, Anna Sureda Balarí, Ivan Špıčka, Sosana Delimpasi, Marek Hus, Vera Zherebtsova, Christopher Wård, P. Joy Ho, Roman Hájek, Sebastian Grosicki, Kristin Morris, Maureen Nichols, Benga Kazeem, Elisabet E. Manasanch,
Discussion(0)
No comments yet. Be the first to comment.